A LONG-ACTING CHOLINESTERASE INHIBITOR REVERSES SPATIAL MEMORY DEFICITS IN MICE

被引:71
作者
SWEENEY, JE
HOHMANN, CF
MORAN, TH
COYLE, JT
机构
[1] JOHNS HOPKINS UNIV, SCH MED,DEPT PSYCHIAT,MEYER 4-163,600 N WOLFE ST, BALTIMORE, MD 21205 USA
[2] JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH SCI, DIV NEUROTOXICOL, BALTIMORE, MD 21205 USA
[3] JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA
[4] JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL, BALTIMORE, MD 21205 USA
关键词
D O I
10.1016/0091-3057(88)90325-5
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
The effects of the long-acting acetylcholinesterase (AChE) inhibitor, galanthamine, on spatial memory were investigated in mice. Mice received ibotenic acid or sham lesions to the nucleus basalis magnocellularis (nBM). Groups of nBM-lesioned and control mice were then trained on a modified Morris swim maze task. Each mouse was first placed on a platform and then into quadrants of the swim tank in a random order. Time required to find the hidden platform was measured. In different phases of testing, the animal had to find a platform that either remained in the same quadrant (reference memory component) or was moved daily (working memory component). The nBM-lesioned mice took significantly longer to find the platform as compared to controls on the working, but not on the reference, memory component of the task. Galanthamine (5.0 mg/kg, IP), given 3.5 hours before testing, improved performance on the working memory task in nBM-lesioned mice by 70% and strikingly impaired performance in controls. Galanthamine''s ability to reverse cognitive deficits induced by nBM lesions and its comparatively long half-life suggest that it may be effective in treating the central cholinergic deficits in Alzheimer''s disease patients.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 43 条
[1]   EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE ON RECOGNITION MEMORY IN MONKEYS WITH IBOTENIC-ACID LESIONS OF THE NUCLEUS BASALIS OF MEYNERT [J].
AIGNER, TG ;
MITCHELL, SJ ;
AGGLETON, JP ;
DELONG, MR ;
STRUBLE, RG ;
PRICE, DL ;
WENK, GL ;
MISHKIN, M .
PSYCHOPHARMACOLOGY, 1987, 92 (03) :292-300
[2]  
ANTONYAN SG, 1986, KHIM FARM ZH+, V20, P172
[4]   REVERSAL OF CENTRAL ANTICHOLINERGIC SYNDROME BY GALANTHAMINE [J].
BARAKA, A ;
HARIK, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1977, 238 (21) :2293-2294
[5]   SELECTIVE MEMORY LOSS FOLLOWING NUCLEUS BASALIS LESIONS - LONG-TERM BEHAVIORAL RECOVERY DESPITE PERSISTENT CHOLINERGIC DEFICIENCIES [J].
BARTUS, RT ;
FLICKER, C ;
DEAN, RL ;
PONTECORVO, M ;
FIGUEIREDO, JC ;
FISHER, SK .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1985, 23 (01) :125-135
[6]   SHORT-TERM-MEMORY IN RHESUS-MONKEY - DISRUPTION FROM ANTI-CHOLINERGIC SCOPOLAMINE [J].
BARTUS, RT ;
JOHNSON, HR .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1976, 5 (01) :39-46
[7]   PHYSOSTIGMINE AND RECENT MEMORY - EFFECTS IN YOUNG AND AGED NONHUMAN-PRIMATES [J].
BARTUS, RT .
SCIENCE, 1979, 206 (4422) :1087-1089
[8]   ANTICHOLINESTERASE ACTIVITY OF A NEW CARBAMATE, HEPTYLPHYSOSTIGMINE, IN VIEW OF ITS USE IN PATIENTS WITH ALZHEIMER-TYPE DEMENTIA [J].
BRUFANI, M ;
MARTA, M ;
POMPONI, M .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 157 (01) :115-120
[9]  
CHAPLYGINA SR, 1976, ZH VYSSH NERV DEYAT+, V26, P1091
[10]   ALZHEIMERS-DISEASE - A DISORDER OF CORTICAL CHOLINERGIC INNERVATION [J].
COYLE, JT ;
PRICE, DL ;
DELONG, MR .
SCIENCE, 1983, 219 (4589) :1184-1190